These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 36646687)

  • 1. CRISPR/Cas9 therapeutics: progress and prospects.
    Li T; Yang Y; Qi H; Cui W; Zhang L; Fu X; He X; Liu M; Li PF; Yu T
    Signal Transduct Target Ther; 2023 Jan; 8(1):36. PubMed ID: 36646687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
    Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
    ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases.
    Sundaresan Y; Yacoub S; Kodati B; Amankwa CE; Raola A; Zode G
    FEBS J; 2023 Nov; 290(22):5248-5269. PubMed ID: 36877952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of gene editing therapeutics.
    Kevadiya BD; Islam F; Deol P; Zaman LA; Mosselhy DA; Ashaduzzaman M; Bajwa N; Routhu NK; Singh PA; Dawre S; Vora LK; Nahid S; Mathur D; Nayan MU; Baldi A; Kothari R; Patel TA; Madan J; Gounani Z; Bariwal J; Hettie KS; Gendelman HE
    Nanomedicine; 2023 Nov; 54():102711. PubMed ID: 37813236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress and Perspective of CRISPR-Cas9 Technology in Translational Medicine.
    Zheng R; Zhang L; Parvin R; Su L; Chi J; Shi K; Ye F; Huang X
    Adv Sci (Weinh); 2023 Sep; 10(25):e2300195. PubMed ID: 37356052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
    Li Y; Glass Z; Huang M; Chen ZY; Xu Q
    Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
    Pei WD; Zhang Y; Yin TL; Yu Y
    Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.
    de Morais CCPL; Correia EM; Bonamino MH; Vasconcelos ZFM
    Hum Gene Ther; 2024 Oct; 35(19-20):781-797. PubMed ID: 39276086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.